37
Participants
Start Date
June 30, 2022
Primary Completion Date
December 12, 2023
Study Completion Date
May 31, 2024
JNJ-73763989
JNJ-73763989 will be administered subcutaneously.
PD-1 inhibitor
PD-1 inhibitor will be administered as IV infusion.
Tenofovir Disoproxil
Tenofovir disoproxil film-coated tablets will be administered orally.
Tenofovir Alafenamide
TAF film-coated tablets will be administered orally.
Entecavir
ETV film-coated tablets will be administered orally.
E-DA Hospital, Kaohsiung City
Hosp Univ Vall D Hebron, Barcelona
Hopital Saint Joseph, Marseille
Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano, Milan
Hosp. Univ. Pta. de Hierro Majadahonda, Madrid
Linkou Chang Gung Memorial Hospital, Taoyuan District
Istanbul University Cerrahpasa Medical Faculty, Istanbul
Chu Rennes Hopital Pontchaillou, Rennes
Ege University Medical Faculty, Izmir
Hosp. Montecelo, Pontevedra
China Medical University Hospital, Taichung
Kocaeli University Medical Faculty, Kocaeli
Hosp. Gral. Univ. Valencia, Valencia
CHRU Nancy Brabois, Vandœuvre-lès-Nancy
Azienda Ospedaliero Universitaria Pisana, Pisa
Karadeniz Teknik University Medical Faculty, Trabzon
Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City
Hopital Beaujon, Clichy
Toronto General Hospital, Toronto
Fakultni nemocnice Hradec Kralove, Hradec Králové
IKEM, Prague
Universita degli Studi di Roma 'La Sapienza' - Umberto I Policlinico di Roma, Rome
Hacettepe University Medical Faculty, Ankara
Glasgow Royal Infirmary, Glasgow
Kings College Hospital, London
Imperial College London and Imperial College Healthcare NHS Trust, London
Janssen Research & Development, LLC
INDUSTRY